⌘K

Login Start Free

Home/Filings/4/0001213900-22-024305

4//SEC Filing

Xavier Ramnik 4

Accession 0001213900-22-024305

CIK 0001821586other

View on SEC.gov Company Profile

Filed

May 4, 8:00 PM ET

Accepted

May 5, 5:49 PM ET

Size

5.6 KB

Accession

0001213900-22-024305

Insider Transaction Report

Form 4

Period: 2022-04-06

MoonLake ImmunotherapeuticsMLTX

Director

Transactions

Award
Option to Buy
2022-04-06+45,000→ 45,000 total
Exercise: $12.25Exp: 2032-04-06→ Class A ordinary shares, par value $0.0001 per share (45,000 underlying)

Footnotes (1)

[F1]Dr. Xavier was granted 45,000 options on April 6, 2022 pursuant to the MoonLake Immunotherapeutics 2022 Equity Incentive Plan (the "Plan"), vesting one-third on each of April 6, 2023, April 6, 2024 and April 6, 2025, in each case, subject to the terms of the Plan. Each option represents the right to acquire one Class A ordinary share, par value $0.0001 per share, of the Issuer.

Documents

1 file

4
ownership.xmlPrimary

Issuer

MoonLake Immunotherapeutics

CIK 0001821586

Entity typeother

Related Parties

1

filerCIK 0001920780

Filing Metadata

Form type: 4
Filed: May 4, 8:00 PM ET
Accepted: May 5, 5:49 PM ET
Size: 5.6 KB

View on SEC.gov